Back to Peptide Encyclopedia
Weight Loss & MetabolicModerate Evidence
Retatrutide
Triple GLP-1/GIP/Glucagon agonist representing the cutting edge of weight loss research.
Research Only4 protocols
Research-only — no FDA/EMA approval
·Educational information. Not medical advice or a recommendation for use.Key Facts: Retatrutide
Category
Weight Loss & Metabolic
Evidence
Moderate Evidence
Availability
Research Only
Protocols
4
Research Overview & Mechanisms
Triple activation of GLP-1, GIP, and glucagon receptors for maximal metabolic effect.
Reported Research Benefits
Triple mechanism
Significant weight loss
Metabolic enhancement
Available Protocols
Frequently Asked Questions
FAQ
Triple GLP-1/GIP/Glucagon agonist representing the cutting edge of weight loss research.
Advanced Compound Intelligence
—
Human studies
—
Key studies
—
Interactions
Moderate Evidence
Evidence tier
Verified intelligence
Research summaryClinical Evidence
Moderate Evidence
View all studies on PubMedPhase II clinical trials or limited Phase III data available.
Compare Retatrutide
Scientific Sources & Further Reading
Explore peer-reviewed research about Retatrutide:
External links open in new tabs. Always verify information with qualified healthcare providers.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →